Comparison Between Darbapoeitin Alpha and Roxadustat in CKD-related Anemia

Anemia is a common and debilitating complication of end-stage kidney disease (ESKD) that is associated with reduced quality of life and high morbidity and mortality. ESKD-related anemia is associated with many adverse comorbidities and outcomes; however, normalizing the levels of hemoglobin proved to be insignificant in improving most adverse outcomes. This study aims to evaluate the real-world effectiveness and safety of an ESA and a HIF-PHI in patients with CKD-related anemia.

NCT Number	NCT07517744
Lead Sponsor	Ain Shams University Collaborators: Misr International University, October 6 University
Conditions	CKD Anemia, CKD Anemia in Stable Dialysis Patients
Enrollment	35 participants
Start Date	2024-06-01
Primary Completion	2025-06-12 (estimated)
Study Completion	2025-06-12 (estimated)
Updated on ClinicalTrials.gov	2026-04-08